On 29 May 2019, orphan designation (EU/3/19/2167) was granted by the European Commission to BeiGene Ireland Limited, Ireland, for zanubrutinib, also known as (BGB-3111), for the treatment of lymphoplasmatic lymphoma.
|Disease / condition||
Treatment of lymphoplasmacytic lymphoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: